{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:36:44Z","timestamp":1793889404739,"version":"4.8.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited therapeutic options, in which neuroinflammation critically drives disease progression. Regulatory T cells (Tregs) exert potent immunosuppressive and neuroprotective effects, offering great potential for ALS treatment. However, clinical application of Treg therapy is hampered by low peripheral cell abundance and unstable expansion quality. Here, we established and optimized a GMP-grade protocol for sorting and expanding peripheral blood-derived Tregs, and validated cryopreserved apheresis products as feasikble starting materials. Although ALS patient-derived Tregs showed reduced expansion capacity compared with healthy donor counterparts, they maintained comparable purity, stable regulatory phenotypes, and robust immunosuppressive function. Transcriptomic analysis confirmed the lineage fidelity and low pro-inflammatory characteristics of expanded Tregs. Therapeutic efficacy was verified in SOD1G93A ALS and GvHD mouse models with delayed disease progression and relieved inflammation. This study provides standardized GMP manufacturing strategies and solid preclinical evidence to support the ongoing clinical trial (NCT06671236) and facilitate Treg immunotherapy translation for ALS.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1854252","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:23:40Z","timestamp":1782966220000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and efficacy of ex vivo expanded autologous regulatory T cells for the treatment of amyotrophic lateral sclerosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ya","family":"You","sequence":"first","affiliation":[{"name":"Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Dong","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqi","family":"Lu","sequence":"additional","affiliation":[{"name":"Shanghai Saierxin Biomedical Technology Co., Ltd.","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Du","sequence":"additional","affiliation":[{"name":"Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopaedic Department of Tongji Hospital, School of Life Sciences and Technology, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.203","article-title":"The epidemiology of ALS: a conspiracy of genes, environment and time","volume":"9","author":"Al-Chalabi","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/jci99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: from genes to mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.07.025","article-title":"Disruption of nuclear speckle integrity dysregulates RNA splicing in C9ORF72-FTD\/ALS","volume":"112","author":"Wu","year":"2024","journal-title":"Neuron"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2019.1644076","article-title":"ALS-FTLD-linked mutations of SQSTM1\/p62 disrupt selective autophagy and NFE2L2\/NRF2 anti-oxidative stress pathway","volume":"16","author":"Deng","year":"2020","journal-title":"Autophagy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-00537-7","article-title":"TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS","volume":"28","author":"Zuo","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-025-01896-4","article-title":"Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis","volume":"28","author":"Cheng","year":"2025","journal-title":"Nat Neurosci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1933-9","article-title":"Inflammation in ALS\/FTD pathogenesis","volume":"137","author":"McCauley","year":"2019","journal-title":"Acta Neuropathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel","year":"2022","journal-title":"JAMA Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tins.2023.11.003","article-title":"White matter injury across neurodegenerative disease","volume":"47","author":"Festa","year":"2024","journal-title":"Trends Neurosci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0824-5","article-title":"Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery","volume":"565","author":"Ito","year":"2019","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0324-7","article-title":"Transcriptional and epigenetic basis of Treg cell development and function: Its genetic anomalies or variations in autoimmune diseases","volume":"30","author":"Ohkura","year":"2020","journal-title":"Cell Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex147","article-title":"Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and Treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4103\/nrr.nrr-d-23-01385","article-title":"T cell interactions with microglia in immune-inflammatory processes of ischemic stroke","volume":"20","author":"Zheng","year":"2025","journal-title":"Neural Regener Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41593-025-01877-7","article-title":"Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent Treg-microglia crosstalk","volume":"28","author":"Izzy","year":"2025","journal-title":"Nat Neurosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04226-0","article-title":"Circulating levels of T-cell traits and the risk of amyotrophic lateral sclerosis: A mendelian randomization study","volume":"61","author":"Lu","year":"2024","journal-title":"Mol Neurobiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0035","article-title":"Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: A study of humans and a transgenic mouse model","volume":"75","author":"Sheean","year":"2018","journal-title":"JAMA Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89530","article-title":"ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity","volume":"2","author":"Beers","year":"2017","journal-title":"JCI Insight"},{"key":"B23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.26375","article-title":"Tregs attenuate peripheral oxidative stress and acute phase proteins in ALS","volume":"92","author":"Beers","year":"2022","journal-title":"Ann Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200019","article-title":"Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis","volume":"9","author":"Thonhoff","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory t cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.697854","article-title":"Regulatory T cells in\u00a0GVHD therapy","volume":"12","author":"Guo","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-003996","article-title":"High donor FoxP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic sct","volume":"108","author":"Rezvani","year":"2006","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026446","article-title":"Donor regulatory T-cell therapy to prevent graft-versus-host disease","volume":"145","author":"Meyer","year":"2012","journal-title":"Clin Trials And Observations"},{"key":"B29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nri821","article-title":"CD4+ CD25+ suppressor T cells: more questions than answers","volume":"2","author":"Shevach","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.2.287","article-title":"CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production","volume":"188","author":"Shevach","year":"1998","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12992","article-title":"Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients","volume":"45","author":"Ma","year":"2018","journal-title":"Clin Exp Pharmocol Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109699","article-title":"Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment","volume":"36","author":"Banerjee","year":"2021","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2026.124359","article-title":"LAG-3 at the crossroads: A context-dependent regulator of Tregs and autoimmunity inflammatory disorders","volume":"394","author":"Yu","year":"2026","journal-title":"Life Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:23:41Z","timestamp":1782966221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1854252"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1854252","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1854252"}}